Better Buy: Biogen vs. Bristol Myers Squibb

Buying shares of a company that's in a transition can sometimes pay off nicely. Such transitions can lead to a resurgence in growth that fuels a major stock jump.

Biogen (NASDAQ: BIIB) and Bristol Myers Squibb (NYSE: BMY) stand out as two drugmakers who are in transition periods. Biogen is expanding beyond its core focus on multiple sclerosis. Bristol Myers Squibb has moved into new areas thanks to its acquisition of Celgene in November 2019.

The transitions for Biogen and BMS haven't brought good news for investors so far this year, though. Both stocks are down more than 9% year to date. But both biopharmaceutical companies have key opportunities to turn things around in the near future. Which stock is the better pick for investors now?

Source Fool.com